Sihuan Pharmaceutical Holdings Group Past Earnings Performance
Past criteria checks 0/6
Sihuan Pharmaceutical Holdings Group's earnings have been declining at an average annual rate of -11.1%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 7.8% per year.
Key information
-11.1%
Earnings growth rate
-11.5%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | -7.8% |
Return on equity | -5.0% |
Net Margin | -2.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Revenue & Expenses Breakdown
How Sihuan Pharmaceutical Holdings Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,861 | -54 | 911 | 578 |
30 Jun 23 | 1,773 | -2,041 | 898 | 773 |
31 Mar 23 | 1,977 | -1,996 | 961 | 855 |
31 Dec 22 | 2,181 | -1,951 | 1,023 | 937 |
30 Jun 22 | 2,595 | -144 | 1,139 | 992 |
31 Mar 22 | 2,817 | 141 | 1,134 | 930 |
31 Dec 21 | 3,038 | 427 | 1,129 | 868 |
30 Sep 21 | 3,304 | 681 | 1,102 | 815 |
30 Jun 21 | 3,317 | 945 | 1,049 | 762 |
31 Mar 21 | 2,891 | 727 | 954 | 746 |
31 Dec 20 | 2,464 | 508 | 859 | 729 |
30 Sep 20 | 2,370 | -14 | 792 | 698 |
30 Jun 20 | 2,275 | -537 | 725 | 666 |
31 Mar 20 | 2,577 | -1,623 | 721 | 633 |
31 Dec 19 | 2,878 | -2,709 | 717 | 599 |
30 Sep 19 | 3,088 | -1,927 | 722 | 566 |
30 Jun 19 | 3,297 | -1,144 | 727 | 534 |
31 Mar 19 | 3,107 | 238 | 697 | 507 |
31 Dec 18 | 2,917 | 1,620 | 667 | 480 |
30 Sep 18 | 2,751 | 1,496 | 580 | 482 |
30 Jun 18 | 2,584 | 1,372 | 494 | 484 |
31 Mar 18 | 2,665 | 1,411 | 523 | 394 |
31 Dec 17 | 2,746 | 1,449 | 553 | 304 |
30 Sep 17 | 2,992 | 1,632 | 653 | 152 |
30 Jun 17 | 3,238 | 1,815 | 754 | 0 |
31 Mar 17 | 3,212 | 1,761 | 720 | 0 |
31 Dec 16 | 3,186 | 1,708 | 686 | 0 |
30 Sep 16 | 2,984 | 1,528 | 627 | 0 |
30 Jun 16 | 2,781 | 1,347 | 568 | 0 |
31 Mar 16 | 2,974 | 1,705 | 590 | 0 |
31 Dec 15 | 3,167 | 2,062 | 611 | 0 |
30 Sep 15 | 3,321 | 2,181 | 648 | 0 |
30 Jun 15 | 3,474 | 2,299 | 685 | 0 |
31 Mar 15 | 3,279 | 1,985 | 658 | 0 |
31 Dec 14 | 3,084 | 1,671 | 630 | 0 |
30 Sep 14 | 2,365 | 1,581 | 0 | 0 |
30 Jun 14 | 1,645 | 1,491 | -631 | 0 |
31 Mar 14 | 2,116 | 1,388 | -83 | 0 |
31 Dec 13 | 2,586 | 1,285 | 466 | 0 |
30 Sep 13 | 4,355 | 1,182 | 2,410 | 0 |
Quality Earnings: 460 is currently unprofitable.
Growing Profit Margin: 460 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 460 is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.
Accelerating Growth: Unable to compare 460's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 460 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.1%).
Return on Equity
High ROE: 460 has a negative Return on Equity (-5.02%), as it is currently unprofitable.